EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database

Mari Maese iD, Nozomi Ito, Haruka Shiokawa iD, Shingo Kondo iD, Yuko Okamoto, Hiroki Iwata, Shunsuke Urushibata, Katsunori Yamaura iD

Pharmacy · 08.08.2026 · 14 (5) · 117

DOI: 10.3390/pharmacy14050117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy, online erschienen am 08.08.2026. Verfasst von Mari Maese und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Sciences, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“Triple whammy” prescriptions, combining non-steroidal anti-inflammatory drugs (NSAIDs), renin–angiotensin system (RAS) inhibitors, and diuretics, increase acute kidney injury (AKI) risk. To clarify the frequency and profiles of these prescriptions and identify vulnerable populations, we analyzed the AHI partners database to estimate the number of individuals prescribed these three drug classes. In the single-agent analysis, loxoprofen was the most commonly prescribed NSAID (66.3%), olmesartan (19.4%) and telmisartan (15.9%) were the predominant RAS inhibitors, and furosemide (19.6%) and spironolactone (16.0%) were the most frequently used diuretics. Dual-drug combinations showed patterns consistent with the single-agent results for NSAIDs and diuretics. By contrast, sacubitril/valsartan was the most common RAS inhibitor when combined with diuretics, frequently utilized for heart failure management. In triple whammy prescriptions, NSAIDs and diuretics patterns mirrored those of single-agents. The annual number of triple whammy prescriptions showed a statistically significant downward trend over the study period by the Mann–Kendall trend test (p = 0.048). Notably, sacubitril/valsartan was the leading RAS inhibitor (46/199 patients, 23%), showing a higher proportion than its single-agent use (7.4%). Heart failure patients prescribed these two causative drugs are highly vulnerable to “triple whammy” prescriptions. Awareness of inadvertent NSAID additions is warranted to mitigate potential AKI risks.

Schlagwörter

Stichwörter der Autor:innen

acute kidney injurydiureticnon-steroidal anti-inflammatory drugrenin–angiotensin system inhibitor

Autor:innen und Institutionen

  • Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Sciences, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan.
  • Keio University Community Pharmacy, Tokyo 105-8512, Japan.
  • Japan Pharmacy Collaboration for Heart Failure, Kanagawa 250-0011, Japan.

ORCID-Profile: Mari Maese, Haruka Shiokawa, Shingo Kondo, Katsunori Yamaura

Förderung

  • Japan Pharmaceutical Association

Zitieren

APA

Maese, M., Ito, N., Shiokawa, H., Kondo, S., Okamoto, Y., Iwata, H., Urushibata, S., & Yamaura, K. (2026). Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database. Pharmacy, 14(5), 117. https://doi.org/10.3390/pharmacy14050117

Vancouver

Maese M, Ito N, Shiokawa H, Kondo S, Okamoto Y, Iwata H, et al. Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database. Pharmacy. 2026;14(5):117. doi:10.3390/pharmacy14050117

BibTeX
@article{Maese2026,
  author = {Maese, Mari and Ito, Nozomi and Shiokawa, Haruka and Kondo, Shingo and Okamoto, Yuko and Iwata, Hiroki and Urushibata, Shunsuke and Yamaura, Katsunori},
  title = {Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database},
  journal = {Pharmacy},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {117},
  doi = {10.3390/pharmacy14050117}
}
Kostenlos starten →